Navigation Links
Thalidomide Improves Outcomes for Older Myeloma Patients
Date:10/5/2007

Adding the drug to standard chemo boosted survival, study found

FRIDAY, Oct. 5 (HealthDay News) -- Elderly patients with multiple myeloma live longer when thalidomide is added to standard combination chemotherapy treatment, a new study finds.

The finding could be the first real treatment advance for these types of patients in decades, the researchers said.

Standard chemotherapy for elderly patients involves two drugs, melphalan plus prednisone, explained a French team who are publishing their findings in this week's issue of The Lancet medical journal.

The study included 447 previously untreated patients, ages 65 to 75, divided into three groups: 196 received melphalan and prednisone (MP); 125 received MP plus thalidomide (MPT); and 126 received reduced-intensity stem cell transplantation using melphalan (MEL100).

Median survival times were: 33.2 months in the MP group; 51.6 months in the MPT group; and 38.8 in the MEL100 group.

MPT patients were 41 percent less likely to die than MP patients and 31 percent less likely to die than MEL100 patients.

"Our study has shown that the addition of thalidomide to standard melphalan and prednisone significantly extended survival for elderly patients with previously untreated multiple myeloma," wrote a team led by Dr. Thierry Facon, of the Centre Hospitalier Universitaire de Lille. "We noted that the MPT regimen was better than the MP regimen in terms of response, including complete response, overall survival, and progression-free survival."

The researchers concluded that the results "provide strong evidence to suggest that the MPT combination, should, at present, be the reference treatment for previously untreated elderly patients with multiple myeloma. After 40 years of unsuccessful attempts to find a more effective treatment than the standard MP, the MPT combination opens an era of progress for elderly patients with the disease."

Two experts who weren't involved in the study agree. In an accompanying Lancet Comment, Dr. Antonio Palumbo and Dr. Mario Boccadoro wrote that "we now have extensive evidence to support the introduction of MPT as the standard of care for elderly patients with multiple myeloma."

More information

The American Cancer Society outlines treatment options for multiple myeloma.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 5, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Thalidomide may stage a comeback
2. Thalidomide is the new approved drug for treating multiple cancers
3. Thalidomide for Tumor Treatment
4. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
5. Collagen improves voice quality in Parkinsonism
6. Breakfast improves memory
7. A new hearing device improves hearing
8. Hormone replacement therapy improves sexual function
9. New therapy improves quality of life for cancer
10. Adding contrast improves ultrasounds ability to detect prostate cancer
11. Switching drugs regularly improves HIV treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 ... the lift is mounted on wheels, it can be wheeled out of the way and ... fasten to the deck. "We have transformed the feedback from customers into specific enhancements and ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a ... witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation ... educator interacting with countless women who had little knowledge of the female characters portrayed ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: